Joanne Blum
Medical Oncology · Dallas, TXNPI 1285676411
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 63.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $18,567 and has fallen 99.7% since, to $53 in 2025.
Across 91 payments — averaging $794.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$46K
- Daiichi Sankyo Inc.$8K
- Sanofi$4K
- Puma Biotechnology, Inc.$4K
- Amgen$3K
- AstraZeneca$2K
- plus $6K from 6 others
Across 170 payments — averaging $11,776 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$1.2M
- Pfizer$299K
- Novartis$173K
- Medivation LLC.$150K
- Sanofi US Services Inc.$104K
- Eli Lilly$57K
- plus $19K from 1 others
What the payments were for
- Consulting fees$19,79827%
- Speaking & faculty fees$30,22042%
- Travel & lodging$19,89628%
- Food & beverage$7731%
- Education$120%
- Other$1,6152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 28 | $45,612 |
| Daiichi Sankyo Inc. | 9 | $7,937 |
| Sanofi | 1 | $4,010 |
| Puma Biotechnology, Inc. | 5 | $3,618 |
| Amgen | 8 | $3,385 |
| AstraZeneca | 3 | $2,085 |
| Athenex Pharmaceutical Division, LLC | 5 | $1,850 |
| Novartis | 18 | $1,615 |
| Gilead | 2 | $1,012 |
| Immunomedics, Inc. | 1 | $1,000 |
| AbbVie | 10 | $170 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBRANCE$21,396
- TALZENNA$8,740
- Enhertu$7,679
- Nerlynx$3,560
- XGEVA$3,283
- Oral Paclitaxel$1,500
- Encequidar$1,500
- Trodelvy$1,000
How this compares
$72,313 in reported general payments places this provider in the 85th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.